Fount of Information

AcroBiosystems社 【Featured Product】Full-length CD20 with complete epitopes

この製品に関するご意見・ご照会・お問合せはこちら

Comprehensive_ADC_target_1.png

 Products

Support

Scientific Talk

COVID-19 R&D

About Us

  

【Featured Product】Full-length CD20 with complete epitopes

   


 CD20.png

Target epitopes of anti-CD20 monoclonal antibodies

 

In view of the differences in the binding epitopes of multiple anti-CD20 monoclonal antibodies, it is obvious that antigens with the characteristics of complete epitopes are important for the development of antibody drugs.

 

ACROBiosystems has built multiple technology platforms to develop and produce full-length CD20 to facilitate the anti-CD20 drug R&D. 

 

 

Advantages of full-length CD20 proteins

 

  • Expressed by HEK293: post-translational modification and proper protein folding

 

  • Native conformation and complete antibody binding epitopes

 

  • Suitable for immunization/antibody screening/ELISA/SPR/BLI/FACS

 

High bioactivity and affinity verified by binding to Rituximab and Ofatumumab

  


 

Assay Data

  

His_Tag_ELISA_1.jpgImmobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag (Cat. No. CD0-H52H1) with a linear range of 1-63 ng/mL.

 

Protocol.PNG 

His_Tag_ELISA2.jpg 

Immobilized Ofatumumab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (SPR verified) (Cat. No. CD0-H52H3) with a linear range of 0.4-6 ng/mL (in presence of DDM and CHS).

 

Protocol.PNG

      


 

>> Learn more about full-length CD20 proteins and verification data with free protocols

       

HEK293_Expressed_CD20.jpg

 

>> Learn more about full-length multi-pass transmembrane proteins and technology platforms 

   Three_tech_platforms.jpg


 


 

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。